Featured Research

from universities, journals, and other organizations

Breathe easy with the protein LPCAT1

Date:
April 26, 2010
Source:
Journal of Clinical Investigation
Summary:
The leading cause of death in infants born prematurely is respiratory distress syndrome. It is caused by deficiency in a fat-protein complex known as lung surfactant, which is critical for optimal gas exchange in the lung. New research indicates that the protein LPCAT1 has a crucial role in surfactant generation in vivo in mice and that LPCAT1 activity must be maximal for the transition from the womb to air breathing.

The leading cause of death in infants born prematurely is respiratory distress syndrome. It is caused by deficiency in a fat-protein complex known as lung surfactant, which is critical for optimal gas exchange in the lung. LPCAT1 is a recently identified mouse lung protein predicted, based on in vitro assays, to be involved in the generation of surfactant.

Now, John Shannon and colleagues, at Cincinnati Children's Hospital Medical Center, have demonstrated that LPCAT1 has a crucial role in the generation of surfactant in vivo in mice and that the activity of this protein must be maximal for the transition from the womb to air breathing.

They therefore speculate that decreased LPCAT1 expression, as a result of mutations in the gene responsible for making this protein, might underlie the fatal respiratory distress syndrome observed in a subset of newborn infants.

The research appears in the Journal of Clinical Investigation.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Journal Reference:

  1. James P. Bridges, Machiko Ikegami, Lauren L. Brilli, Xueni Chen, Robert J. Mason and John M. Shannon. LPCAT1 regulates surfactant phospholipid synthesis and is required for transitioning to air breathing in mice. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI38061

Cite This Page:

Journal of Clinical Investigation. "Breathe easy with the protein LPCAT1." ScienceDaily. ScienceDaily, 26 April 2010. <www.sciencedaily.com/releases/2010/04/100419172850.htm>.
Journal of Clinical Investigation. (2010, April 26). Breathe easy with the protein LPCAT1. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/04/100419172850.htm
Journal of Clinical Investigation. "Breathe easy with the protein LPCAT1." ScienceDaily. www.sciencedaily.com/releases/2010/04/100419172850.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins